Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07DOW
|
|||
| Former ID |
DNC007629
|
|||
| Drug Name |
(1H-pyrazol-1-yl)(o-tolyl)methanone
|
|||
| Synonyms |
AC1LEF7F; Methanone, (2-methylphenyl)-1H-pyrazol-1-yl-; N-Benzoylpyrazole deriv., 26; SCHEMBL5091107; CHEMBL243419; 2-methylphenyl pyrazolyl ketone; ZINC52093; BDBM23718; MolPort-001-495-866; STK458861; AKOS003267448; MCULE-5548346973; (2-methylphenyl)-pyrazol-1-ylmethanone; ST073761; 312317-26-3; 1-[(2-methylphenyl)carbonyl]-1H-pyrazole; (2-methylphenyl)(1H-pyrazol-1-yl)methanone; SR-01000520970; SR-01000520970-1
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H10N2O
|
|||
| Canonical SMILES |
CC1=CC=CC=C1C(=O)N2C=CC=N2
|
|||
| InChI |
1S/C11H10N2O/c1-9-5-2-3-6-10(9)11(14)13-8-4-7-12-13/h2-8H,1H3
|
|||
| InChIKey |
RYSRFZOAAPABLM-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neutrophil elastase (NE) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Transcriptional misregulation in cancer | |||
| Systemic lupus erythematosus | ||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
| C-MYB transcription factor network | ||||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| WikiPathways | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
| Human Complement System | ||||
| Degradation of collagen | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.